NCT03112889View on ClinicalTrials.gov

Sodium Valproate for GSDV

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 5, 2017

Study Completion Date

April 5, 2017

Conditions
Glycogen Storage Disease Type VMcArdle Disease
Interventions
DRUG

Sodium Valproate

Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.

Trial Locations (2)

Unknown

Rigshospitalet, Copenhagen

WC1N 3BG

MRC Centre for Neuromuscular Diseases, London

All Listed Sponsors
lead

University College, London

OTHER

NCT03112889 - Sodium Valproate for GSDV | Biotech Hunter | Biotech Hunter